Association of XPC Gene Polymorphisms with Prostate Cancer Risk

Kahnamouei, Shima A; Narouie, Behzad; Sotoudeh, Mehdi; Mollakouchekian, Mohammad J; Simforoosh, Nasser; Ziaee, Seyed Amir Mohsen; Samzadeh, Mohammad; Afshari, Mahdi; Jamaldini, Seyed Hamid; Imeni, Mahdieh; Hasanzad, Mandana

doi:10.7754/clin.lab.2015.150914

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies have shown varied increases in PC risk with other XPC polymorphisms ( 91 , 135 ) ( Table 1 ). It does not appear that XPC polymorphisms are associated with more advanced disease in PC, and similarly, studies did not find an association between XPC gene polymorphisms and Gleason score (a measure of histologic PC staging which correlates to prognosis) ( 89 , 92 ). However, using TCGA data, low XPC expression was associated with worse overall survival in PC, similar to analyses in many other solid organ tumors ( 135 ).…”

Section: Xpc In Solid Cancersmentioning

confidence: 99%

Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies

2022

View full text Add to dashboard Cite

Xeroderma pigmentosum complementation group C (XPC) is a DNA damage recognition protein essential for initiation of global-genomic nucleotide excision repair (GG-NER). Humans carrying germline mutations in the XPC gene exhibit strong susceptibility to skin cancer due to defective removal via GG-NER of genotoxic, solar UV-induced dipyrimidine photoproducts. However, XPC is increasingly recognized as important for protection against non-dermatologic cancers, not only through its role in GG-NER, but also by participating in other DNA repair pathways, in the DNA damage response and in transcriptional regulation. Additionally, XPC expression levels and polymorphisms likely impact development and may serve as predictive and therapeutic biomarkers in a number of these non-dermatologic cancers. Here we review the existing literature, focusing on the role of XPC in non-dermatologic cancer development, progression, and treatment response, and highlight possible future applications of XPC as a prognostic and therapeutic biomarker.

show abstract

Section: Xpc In Solid Cancersmentioning

confidence: 99%

Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies

2022

View full text Add to dashboard Cite

show abstract

“…However, there are vague conclusions about the relationship between XPC rs2228001 A/C polymorphism and PCa susceptibility in different case‐controlled studies. Hence, a systematic analysis based on all eligible studies was conducted to further investigate the correlation between the XPC rs2228001 A/C polymorphism and PCa risk 17‐28 …”

Section: Introductionmentioning

confidence: 99%

“…Hence, a systematic analysis based on all eligible studies was conducted to further investigate the correlation between the XPC rs2228001 A/C polymorphism and PCa risk. [17][18][19][20][21][22][23][24][25][26][27][28]…”

mentioning

confidence: 99%

Effects of Xeroderma pigmentosum group C polymorphism on the likelihood of prostate cancer

Yan

Wen

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Numerous studies have assessed the association between xeroderma pigmentosum complementation group C (XPC) polymorphisms and susceptibility of prostate cancer (PCa); however, the findings remain inconsistent. Methods We performed an updated analysis utilizing data from electronic databases to obtain a more accurate estimation of the relationship between XPC rs2228001 A/C polymorphism and PCa risk. We further used in silico tools to investigate this correlation. Results Totally, 5,305 PCa cases and 6,499 control subjects were evaluated. When all studies pooled together, we detected no positive result (recessive genetic model: OR = 1.14, 95% CI = 0.93‐1.40, Pheterogeneity = 0.001, P = .212); nevertheless, the XPC rs2228001 A/C variant was associated with PCa risk in Asian descendants in the subgroup analysis (OR = 1.21, 95% CI = 1.01‐1.43, Pheterogeneity = 0.008, P = .034). In silico tools showed that more than 20 proteins can participate in the protein crosstalk with XPC. The expression of XPC was down‐regulated in all Gleason scores of prostate cancer. Conclusions The present study indicated that the XPC rs2228001 A/C variant may be associated with elevated PCa risk in Asian patients.

show abstract

“…The XRCC1 polymorphism rs1799782 (C194T) was reported to correlate with tumor metastasis and molecular subtypes in breast cancer and XRCC1 Arg399Gln with bladder cancer ( 19 , 20 ). In addition, the XPC intron11 C/A polymorphism and Lys939Gln are risk factors for prostate cancer ( 21 , 22 ).…”

Section: Introductionmentioning

confidence: 99%

Noninvasive circulating tumor cell and urine cellular XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphism detection as an effective screening panel for genitourinary system cancers

Wu¹,

Che²,

Wang³

et al. 2019

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Valid cancer screening and treatment monitoring are critical for cancer patients. Although genitourinary system cancers have a high recurrence rate, when diagnosed, patients undergo surgery promptly. We sought to explore sensitive and noninvasive screening and postoperative recurrence monitoring methods, such as circulating tumor cells (CTCs) or tumor susceptibility gene detection, to determine their appropriateness for genitourinary system cancers.Methods: We adopted multiple detection methods. Enrichment-immunofluorescence in situ hybridization (SE-iFISH) was employed to detect CTCs from the peripheral blood of patients, and Agena Bioscience MassARRAY was used to detect single-nucleotide polymorphisms (SNPs) in tumor susceptibility genes from urine cells.Results: In our research, CTCs showed a 76.92% positivity rate among 26 genitourinary system cancer patients, and the number of CTCs was consistent with the stage of cancer. In monitoring for bladder cancer (BC) recurrence, CTCs were more prevalent than urine cytology (66.67% vs. 41.67%). To our surprise, urine cellular XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphisms were specifically found in cancer patients but not in patients with inflammation or in healthy individuals. XPC polymorphism (rs2228001, A2815C) rates were 30.77%, 40%, and 50% in bladder cancer, renal carcinoma, and prostate cancer patients, respectively, and those for XRCC1 (rs25487, G1196A) were 3.85%, 20%, and 25%, respectively.Conclusions: As a common biomarker, CTCs showed remarkable performance in cancer screening and monitoring. The noninvasive panel comprising CTCs and XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphisms showed high sensitivity (positive rate: 92.86%) and is suitable for genitourinary system cancer screening.

show abstract

Association of XPC Gene Polymorphisms with Prostate Cancer Risk

Cited by 5 publications

References 0 publications

Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies

Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies

Effects of Xeroderma pigmentosum group C polymorphism on the likelihood of prostate cancer

Noninvasive circulating tumor cell and urine cellular XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphism detection as an effective screening panel for genitourinary system cancers

Contact Info

Product

Resources

About